NICE does not recommend Shire’s pancreatic cancer drug
3 April 2017 | By Niamh Marriott, Junior Editor
The National Institute or Health and Care Excellence (NICE) has published final guidance that does not recommend pegylated liposomal irinotecan (Onivyde, Shire).